DLL4 and ovarian carcinoma: A bispecific anti-DLL4/anti-VEGF antibody, navicixizumab (OMP-305B83), was evaluated in several early-phase CTs of metastatic colorectal cancer (NCT03035253), platinum-resistant ovarian cancer in combination with paclitaxel (NCT03030287), and advanced solid tumors (NCT02298387), where it showed preliminary signs of antitumor activity often associated with cardiovascular adverse events such as arterial and pulmonary hypertension, being most promising in ovarian cancer [235].